Frailty profile precluding standard FOLFOX+nivo / FLOT in gastric cancer: ECOG ≥3, OR (ag...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-GASTRIC-FRAILTY-AGE |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | DIS-GASTRIC |
| Sources | SRC-ESMO-GASTRIC-2024 SRC-NCCN-GASTRIC-2025 |
Red Flag Origin
| Definition | Frailty profile precluding standard FOLFOX+nivo / FLOT in gastric cancer: ECOG ≥3, OR (age ≥75 + Charlson ≥3), OR composite (age ≥70 + albumin <3.0 + ≥10% weight loss + sarcopenia — common in gastric cancer). Triggers regimen de-escalation (5-FU / capecitabine monotherapy, omit ICI/biologic). |
|---|---|
| Clinical direction | de-escalate |
| Category | frailty-age |
Trigger Logic
{
"any_of": [
{
"comparator": ">=",
"finding": "ecog",
"threshold": 3
},
{
"all_of": [
{
"comparator": ">=",
"finding": "age",
"threshold": 70
},
{
"comparator": "<",
"finding": "albumin_g_dl",
"threshold": 3.0
},
{
"comparator": ">=",
"finding": "weight_loss_pct_3mo",
"threshold": 10
}
]
}
],
"type": "composite_score"
}
Notes
Pre-treatment nutrition optimization (PEG/J-tube, parenteral nutrition bridge) often required. Nivolumab-containing regimens have lower symptomatic toxicity than FLOT for elderly — ATTRACTION-4 included ECOG 0-1 only; real-world frail elderly: capecitabine + nivolumab is reasonable de-escalation.
Used By
Indications
IND-GASTRIC-METASTATIC-1L-CLDN18-2-ZOLBETUXIMAB- IND-GASTRIC-METASTATIC-1L-CLDN18-2-ZOLBETUXIMABIND-GASTRIC-METASTATIC-1L-FGFR2B-BEMARITUZUMAB- IND-GASTRIC-METASTATIC-1L-FGFR2B-BEMARITUZUMABIND-GASTRIC-METASTATIC-1L-HER2-TOGA- IND-GASTRIC-METASTATIC-1L-HER2-TOGAIND-GASTRIC-METASTATIC-2L-HER2-TDXD- IND-GASTRIC-METASTATIC-2L-HER2-TDXDIND-GASTRIC-METASTATIC-2L-RAMUCIRUMAB-PACLITAXEL- IND-GASTRIC-METASTATIC-2L-RAMUCIRUMAB-PACLITAXELIND-GASTRIC-METASTATIC-3L-TAS102- IND-GASTRIC-METASTATIC-3L-TAS102